Quinn Anthony G.
Known title: President & CEOCIK: 0001532219
Quinn Anthony G.'s purchase track record
Quinn Anthony G. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2022 | SYRE | $469K | -64.3% | -75.4% | -3.3% |
| 12/9/2021 | SYRE | $199K | -41.4% | -79.9% | -13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SYRE | ▲ Buy | Open Market | 80,079 | $188K | 3/16/2022 | View on chart |
| SYRE | ▲ Buy | Open Market | 42,417 | $79K | 3/15/2022 | View on chart |
| SYRE | ▲ Buy | Open Market | 67,472 | $130K | 3/14/2022 | View on chart |
| SYRE | ▲ Buy | Open Market | 34,777 | $72K | 3/11/2022 | View on chart |
| SYRE | ▲ Buy | Open Market | 10,526 | $39K | 12/10/2021 | View on chart |
| SYRE | ▲ Buy | Open Market | 43,108 | $159K | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.